Kelly Money
4K posts




📣 JUST IN: $AZN AstraZeneca Ends Vaxzevria Globally Citing Commercial Reasons, Amid Safety Concerns $PFE $MRNA $JNJ $ABBV $LLY 👉 Key Highlights: 📍 AstraZeneca withdraws Vaxzevria globally, starting in EU. 📍 Company cites commercial reasons, not safety, for withdrawal. 📍 TTS linked to vaccine in very rare cases, admits AstraZeneca. 📍 Over 6.5 million lives saved by Vaxzevria, claims the company. 📍 81 deaths in the UK linked to TTS from the vaccine. 📍 Legal actions ongoing with claims against vaccine side effects. 📍 No approval for Vaxzevria in the US; replaced by other vaccines in the UK. 👉 Context/Background: AstraZeneca's Vaxzevria, once a beacon of hope in the COVID-19 pandemic, is being phased out globally. Initially celebrated, it faced scrutiny over rare but severe side effects. Its withdrawal marks a significant shift in the landscape of pandemic response vaccines. 👉 Why This Matters: 📍 Reflects evolving dynamics in vaccine confidence and market demand. 📍 May influence public trust in vaccine safety and pharmaceutical transparency. 👉 Market Insights: 📍 Pharmaceutical and healthcare markets may see shifts in vaccine demand and regulatory scrutiny. 👉 Expert Statement: 🗨️ "Our priority remains patient safety, and the benefits of vaccination still outweigh the risks," - AstraZeneca spokesperson. 👉 Impact & Recommendations: 📍 Healthcare systems and providers must navigate changing vaccine landscapes and public perceptions. 📍 Patients and healthcare consumers should stay informed about vaccine developments and safety profiles. 🔄 Follow @AIStockSavvy for real-time updates. Don’t forget to like, retweet, and turn on notifications for unparalleled insights.












